Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.

In recent years many new agents have been introduced into clinical practice to treat metastatic renal cell carcinoma. Some of these agents are tyrosine kinase inhibitors, which have different adverse events compared to chemotherapy or immunotherapy. We describe the case of a man treated with pazopanib as first-line therapy for metastatic disease, demonstrating the efficacy, good tolerability and easy management of some side effects of this tyrosine kinase inhibitor. The patient, who presented with lung metastases, started therapy in November 2012 and was alive and in continuous response at the time of writing (November 2014). We controlled the elevation of transaminase levels with low-dose corticosteroid administration. The patient had no other significant adverse events (apart from dysgeusia and grade 1 diarrhea), he had good quality of life, and his performance status throughout the treatment was very good (ECOG 0).